These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 9241660

  • 1. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.
    Crespi CL, Miller VP.
    Pharmacogenetics; 1997 Jun; 7(3):203-10. PubMed ID: 9241660
    [Abstract] [Full Text] [Related]

  • 2. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
    Yamazaki H, Inoue K, Chiba K, Ozawa N, Kawai T, Suzuki Y, Goldstein JA, Guengerich FP, Shimada T.
    Biochem Pharmacol; 1998 Jul 15; 56(2):243-51. PubMed ID: 9698079
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.
    Yamazaki H, Shimada T.
    Arch Biochem Biophys; 1997 Oct 01; 346(1):161-9. PubMed ID: 9328296
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor.
    Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD.
    J Pharmacol Exp Ther; 2000 May 01; 293(2):453-9. PubMed ID: 10773015
    [Abstract] [Full Text] [Related]

  • 7. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K, Yamazaki H, Imiya K, Akasaka S, Guengerich FP, Shimada T.
    Pharmacogenetics; 1997 Apr 01; 7(2):103-13. PubMed ID: 9170147
    [Abstract] [Full Text] [Related]

  • 8. CYP2C19 participates in tolbutamide hydroxylation by human liver microsomes.
    Wester MR, Lasker JM, Johnson EF, Raucy JL.
    Drug Metab Dispos; 2000 Mar 01; 28(3):354-9. PubMed ID: 10681382
    [Abstract] [Full Text] [Related]

  • 9. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone.
    Baldwin SJ, Clarke SE, Chenery RJ.
    Br J Clin Pharmacol; 1999 Sep 01; 48(3):424-32. PubMed ID: 10510156
    [Abstract] [Full Text] [Related]

  • 10. Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes.
    Transon C, Lecoeur S, Leemann T, Beaune P, Dayer P.
    Eur J Clin Pharmacol; 1996 Sep 01; 51(1):79-85. PubMed ID: 8880056
    [Abstract] [Full Text] [Related]

  • 11. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
    Takahashi H, Kashima T, Nomoto S, Iwade K, Tainaka H, Shimizu T, Nomizo Y, Muramoto N, Kimura S, Echizen H.
    Pharmacogenetics; 1998 Oct 01; 8(5):365-73. PubMed ID: 9825828
    [Abstract] [Full Text] [Related]

  • 12. The role of CYP2C in the in vitro bioactivation of the contraceptive steroid desogestrel.
    Gentile DM, Verhoeven CH, Shimada T, Back DJ.
    J Pharmacol Exp Ther; 1998 Dec 01; 287(3):975-82. PubMed ID: 9864282
    [Abstract] [Full Text] [Related]

  • 13. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine.
    Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ.
    Eur J Clin Pharmacol; 2001 Apr 01; 57(1):31-6. PubMed ID: 11372587
    [Abstract] [Full Text] [Related]

  • 14. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
    Tang C, Shou M, Rushmore TH, Mei Q, Sandhu P, Woolf EJ, Rose MJ, Gelmann A, Greenberg HE, De Lepeleire I, Van Hecken A, De Schepper PJ, Ebel DL, Schwartz JI, Rodrigues AD.
    Pharmacogenetics; 2001 Apr 01; 11(3):223-35. PubMed ID: 11337938
    [Abstract] [Full Text] [Related]

  • 15. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid.
    Taguchi K, Konishi T, Nishikawa H, Kitamura S.
    Xenobiotica; 1999 Sep 01; 29(9):899-907. PubMed ID: 10548450
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6.
    Voorman RL, Payne NA, Wienkers LC, Hauer MJ, Sanders PE.
    Drug Metab Dispos; 2001 Jan 01; 29(1):41-7. PubMed ID: 11124228
    [Abstract] [Full Text] [Related]

  • 19. 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5.
    Huang Z, Guengerich FP, Kaminsky LS.
    Carcinogenesis; 1998 May 01; 19(5):867-72. PubMed ID: 9635876
    [Abstract] [Full Text] [Related]

  • 20. Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach.
    Venkatakrishnan K, von Moltke LL, Greenblatt DJ.
    J Pharm Sci; 1998 Jul 01; 87(7):845-53. PubMed ID: 9649353
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.